Background: It is estimated that there will be more than 244 000 new prostate cancer cases diagnosed and that more than 40 000 men will die of this disease during 1995. Evidence exists for a hereditary predisposition to prostate cancer, but the propor tion of cases attributable to the inheritance of a specific gene or genes is not large. Some hereditary cancer syndromes in volve more than one tumor site, and some studies have reported a familial association between prostate cancer and other cancers. The presence of other cancers in prostate can cer families may indicate a specific type of hereditary predisposition. Purpose: We studied families that were selected because of the presence of prostate cancer to deter mine whether hereditary prostate cancer is associated with cancers at other sites and possibly with other heritable can cer syndromes. Methods: Data from two distinct study populations were studied retrospectively. The first popula tion consisted of 690 case patients undergoing radical pros tatectomy who were not selected for family history of prostate cancer and 640 control subjects who were the spouses or female companions of the case patients. The second population consisted of 75 multiplex families (i.e., families with multiple cases of prostate cancer) referred be cause they fulfilled the criteria for hereditary prostate can cer. A comparison between case and control populations for the occurrence of 14 aggregated groups of cancer was per formed. Data were analyzed using Poisson regression, and relative risks (RRs) and their 95% confidence intervals (CIs) were calculated. Results: Brothers and fathers of prostate cancer probands have a statistically significant higher risk of prostate cancer than the male first-degree relatives of control subjects (RR = 1.76; 95% Cl = 1.28-2.43). Therefore, the risk for prostate cancer is 76% higher among first-de gree relatives of prostate cancer patients compared with first-degree relatives of control subjects. This higher risk was not modified by an occurrence of breast cancer in the pedigree. Also, a statistically significant higher risk was found for tumors of the central nervous system in hereditary families (RR = 3.02; 95% Cl = 1.08-8.41). Statistically sig nificant higher risks of cancer at other major sites, such as breast, ovary, or endometrium were not observed in these families. Conclusion: Even among families that were specifi cally selected because of the presence of prostate cancer, risks for cancer at other sites appeared not to be increased. Therefore, hereditary prostate cancer appears to be a rela tively site-specific disease, and it does not seem to be a part of other hereditary cancer syndromes. [J Natl Cancer Inst 87:991-996,1995]
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In recent years, much attention has been given to hereditary cancer syndromes, such as familial adenomatous polyposis, hereditary nonpolyposis colon cancer, hereditary breast-ovarian cancer, and Li-Fraumeni syndrome. It is known that some hereditary cancer syndromes are associated with more than one tumor site, whereas others are site specific. The involvement of other tumor sites in hereditary cancer syndromes may indicate that the genetic basis of cancer etiology in these families is heterogeneous (i.e., can be caused by more than one gene or subsets of genes).
Prostate cancer is the most prevalent malignancy among U.S. males. In 1995, there will be more than 244 000 new prostate cancer cases diagnosed and more than 40 000 deaths resulting from this disease (7) . Evidence exists for a hereditary pre disposition to prostate cancer, but the proportion of all cases at tributable to a genetic cause is not large. To characterize familial prostate cancer, our group documented that a positive family history of prostate cancer is a useful index of individual risk (2, 5) and that there is an increased risk for the development of prostate cancer both with an increasing number of affected rela tives and with earlier age at onset in the proband (i.e., identified case patient) (2,4). Using a test of various models to define this familial clustering, it is best explained by the autosomal domi nant inheritance of a rare, yet highly penetrant, gene that pre disposes men to the early development of prostate cancer (4) . A working definition of hereditary prostate cancer has been pro posed to identify families at highest risk (5) . Identification of the genes involved in families with hereditary prostate cancer should provide useful information to better understand the etiol ogy of this disease (5) .
Previous case-control studies have provided evidence for an association between breast cancer and prostate cancer and pos sibly with endometrial and ovarian cancers. Macklin (6) gave evidence for a significantly higher frequency of prostate cancer among relatives of breast cancer patients than among relatives of control groups. She suggested that prostate cancer may be the male equivalent of some female breast cancers. Thiessen (7) reported a coaggregation of prostate cancer and uterine cancer in first-degree (mothers and sisters) and second-degree relatives of women with breast cancer. While Andrieu et al. (8) and Lynch et ah (9) did not find an association between prostate cancer and breast cancer, Anderson and Badzioch (10) reported that a family history of prostate cancer as well as endometrial and ovarian cancers significantly increased the risk of breast cancer.
Large cohort studies have also demonstrated a relationship between prostate and other cancers. One such study (//) made use of the Utah Mormon Genealogical Database in conjunction with the Utah Cancer Registry to test for familial aggregation involving 2821 cases of prostate cancer that occurred in Utah during the years 1958-1981. This study design was used to com pare all cancers and showed prostate cancer to have the fourth strongest degree of familial clustering after lip cancer, skin melanoma, and ovarian cancer. Prostate cancer had a higher de gree of familial aggregation than both colon and breast car cinomas, two solid tumors that are well recognized as having a genetic component. In this study, the ranking for prostate cancer and breast cancer coaggregation within the same pedigree was 20th, whereas prostate cancer and uterine cancer coaggregation ranked 10th.
In a study of Icelandic women with breast cancer, Tulinius et al (12) reported an increased risk of prostate cancer among all male relatives and in uncles, grandfathers, and cousins if the breast cancer proband had a father or brother with either breast cancer or prostate cancer. On the basis of a linkage analysis of seven multiplex families from this Icelandic study, however, Arason et al. (13) found no evidence of linkage to 17q (the loca tion of the BRCA1 gene) in five of the families.
In this article, we studied families that were selected because of the presence of prostate cancer to determine if hereditary prostate cancer could be associated with cancers at other sites and possibly with other heritable cancer syndromes.
Methods
Information from two distinct study populations was used. The first dataset was derived from a case-control study on familial prostate cancer. The second was from a collection of multiplex prostate cancer families (i.e., families with multiple cases of prostate cancer).
Case-Control Families
The study population and the method of data collection are described in detail elsewhere (2) . The case families were ascertained through 741 consecutive probands undergoing radical prostatectomy for primary, clinically localized prostate cancer at The Johns Hopkins Hospital, Baltimore, MD, between 1982 and 1989. Case patients were not selected for family history of disease. The con trol group consisted of the patients' spouses or female companions. In 1989, 690 (93%) probands were interviewed by telephone (17 patients were deceased, 26 could not be located, seven refused to participate, and one turned out to be a duplicate).1 Six hundred forty (94%) of 683 control subjects completed the inter views (58 patients did not have spouses or female companions). The average age for case patients was 62.6 years (range, 34-76 years). This fairly young age dis tribution of a prostate cancer population is explained by the inclusion of patients who were candidates for radical prostateciomy only. The mean age of case patients with and without spousal or companion control subjects was the same. Ninety-six percent of the case patients were white.
Probands and control subjects were asked to recall cancer histories among siblings, children, parents, grandparents, aunts, and uncles. Only biological rela tives (i.e., no half siblings or relatives by marriage) were included. Positive family histories among first-degree relatives were investigated in a sample of the reported cases and found to be accurate (2) . Review of the family histories revealed that cancer occurrence among second-degree relatives was substantially underreported. Therefore, in the present analysis, only first-degree relatives are included. Prostate cancer occurrence in second-degree relatives was used, how ever, in an attempt to characterize hereditary prostate cancer; all probands in the case-control study were classified into one of three subgroups: hereditary, familial, and sporadic. The hereditary subgroup consisted of 31 (4.5% of total) families that met one of the following criteria: 1) a cluster of three or more rela tives affected with prostate cancer within any nuclear family, such as a father and two sons affected or a group of three brothers affected; 2) the occurrence of prostate cancer in each of three successive generations in either the proband's paternal lineage or maternal lineage; or 3) a cluster of two relatives, both af fected with prostate cancer at 55 years of age or younger. These criteria were based on the results of a test of various models to explain familial clustering
(4j).
The familial subgroup consisted of 148 (21.5%) families in which there was a positive family history of prostate cancer, but the aforementioned conditions for inclusion in the hereditary subgroup were not met. Finally, the 511 (74%) simplex (i.e., single-case) families were defined as sporadic.
Multiplex Families
To increase the number of hereditary families, a letter was sent to 8000 board-certified urologists in the United States, requesting referral of multiplex families to the study of Hereditary Prostate Cancer at Johns Hopkins. Names and addresses of patients with diagnosed prostate cancer were provided by the refer ring urologist. Subsequently, in 1993, the proband and living first-degree family members were contacted by telephone to obtain detailed information about fami ly history of all cancers. Also, each patient referral was sent a family cancer form to be filled out and returned to us. The form asked for the name, date of birth, relationship, vital status, cause of death, presence of cancer(s), type of can cels), and date(s) of diagnosis for each first-degree relative in the family. In this article, we report on the first 75 families contacted in this way. Each family met the hereditary prostate cancer criteria of at least three first-degree relatives diag nosed with prostate cancer (5).
Statistical Analysis
Cancer occurrence in first-degree relatives of case patients was compared with the occurrence of cancer in first-degree relatives of control subjects. In an additional analysis, the relatives of case patients were stratified according to the following subgroups: hereditary, familial, or sporadic. In the latter analysis only, the 31 hereditary families were enriched with the 75 multiplex families. Note that, under this study design, the offspring of case patients and control subjects are the same persons. First-degree relatives were therefore limited to parents and siblings of case patients or control subjects. For each of these relatives the num ber of person-years experienced was defined as the minimum of age at inter view, age at death, and age at diagnosis of first primary cancer. Second and subsequent primary cancers were not considered because the corresponding ages at diagnosis were not known. In the original interview, 37 types of cancer were reported. For this analysis, we reclassified these types into 14 groups: prostate, breast, colorectal, other digestive system (pancreas, stomach, liver, gallbladder, alimentary canal, abdominal, and intestinal), urinary tract (bladder and kidney), central nervous system (brain, spine, astrocytoma, and eye), head and neck (head/neck, esophagus, and thyroid), hematopoietic system (leukemia, lym phoma, and spleen), ovary, endometrium, other gynecologic system (cervix and female organ), respiratory system (lung and throat), skin (melanoma and skin), and other (testis, bone, hip/peivic area, back, ieg/knee area, unspecified, metastases, and other). This reclassification was done to reach higher statistical power and to avoid misclassification due to ill-defined tumor sites. The occurrence of these 14 aggregated groups of cancer in relatives of case patients and control subjects was assumed to follow a Poisson distribution. The Poisson distribution is a classic probability model used to describe the distribution of rare events, such as cancer incidence, as follows: piy) -exp (-ji) where y = 0, 1,2,.... Because of the discrete and non-negative nature of count data, it can be as sumed that the logarithm of the expected count is a linear function of ex planatory variables, so that log E(y,) = x ',(3. Here, the regression coefficient for a particular explanatory variable can be interpreted as the logarithm of the ratio of expected counts before and after a one-unit increase in that explanatory variable, with all other explanatory variables held constant. 
Results
The 690 probands and 640 female companions in die casecontrol study had 3259 (of whom 1642 were males) and 3012 (of whom 1518 were males) first-degree relatives, respectively. A total of 62 relatives were excluded from the study because of unknown age. The mean age of case patient relatives was 62.9 years (±SD = 17.8 years). Case patient relatives experienced 185 262 person-years when they were younger than 65 years of age and 19 638 person-years when they were 65 years of age and older. The mean age of the control subject relatives was slightly lower than that of the case patient relatives: 59.8 years (±SD =18.9 years). They experienced 165 913 and 15 214 person-years when they were younger than 65 years of age and 65 years of age and older, respectively.
In Table 1» the RRs of cancer occurrence in case patient rela tives versus control subject relatives are summarized. Brothers and fathers of prostate cancer probands had a statistically sig nificant higher risk of prostate cancer than the first-degree male relatives of control subjects: RR = 1.76; 95% Cl = 1.28-2.43. The risks for cancer of the hematopoietic system (RR = 1.22; 95% Cl = 0.75-1.99), urinary tract (RR = 1.22; 95% Cl = 0.66-2.26), and other sites (RR = 1.28; 95% Cl = 0.70-2.37) were slightly higher as well, but none of these higher risks was sig nificant. The risks for tumors of the central nervous system, head and neck region, ovary, endometrium, other gynecologic system, and respiratory system were lower than in the control Number of probands was 690; number of first-degree relatives was 3259; number of person-years experienced by male and female relatives of probands was 101 233 and 103 667, respectively. tNumber of controls was 640; number of first-degree relatives was 3012; number of person-years experienced by male and female relatives of control sub jects was 89 036 and 91 091, respectively.
$ Adjusted for the effects of sex and age (>65 years versus <65 years). subject relatives, but these decreased risks were not significant either, with the exception of the lower risk for other gynecologic tumors (RR -0.44; 95% Cl = 0.21-0.95). With tests of interac tion between sex and case-control status, it appeared that the RR of other digestive system cancers differed for males and fe males. In males the RR = 0.69; 95% Cl = 0.44-1.07, whereas in females the RR = 1.60; 95% Cl = 1.04-2.47. Of the 690 prostate cancer probands, 107 (15.5%) had at least one sister (n = 54), the mother (n = 49), or both a sister and the mother (n = 4) diagnosed with breast cancer. Table 2 presents the RRs of prostate cancer among first-degree relatives of pros tate cancer probands with and without a sister and/or mother with breast cancer. It appears that the higher risk of prostate cancer for brothers and fathers of probands (RR = 1.76; 95% Cl = 1.28-2.43) was only marginally modified if there was an addi tional breast cancer diagnosed in the nuclear family. Also, the higher risk was not modified by the age at which the breast can cer was diagnosed, i.e., before or after the age of 65 years. Only seven prostate cancer probands had a sister (n = 2) or mother (n = 5) with ovarian cancer. Among the 19 male family members of these probands, no prostate cancer was reported. Twentyeight probands (4.1%) had a sister (n = 12), mother (n = 15), or both a sister and mother (n = 1) with endometrial cancer. Seven prostate cancers were reported among the 69 male relatives of these 28 probands (RR = 2.69; 95% Cl = 1.22-5.90). While this higher risk was statistically significant compared with the con trol subjects (P = .01), it was not significant when compared with other prostate cancer probands who did not have a case of endometrial cancer in the nuclear family (P = .26).
In 94 (13.6%) of the nuclear families of the prostate cancer probands, one additional male relative was affected with pros tate cancer (either a brother or the father). In 12 (1.7%) of the nuclear families, there were two or more affected nonprobands reported. The presence of prostate cancer in a male nonproband in the nuclear family appeared not to have any impact on the risk of breast cancer among female relatives (Table 3) . Com pared with the control subject families, the RR of breast cancer for case patient families without prostate cancer in a nonproband was RR = 1.01; 95% Cl = 0.76-1.35. The RR for case patient families with prostate cancer in a nonproband was RR = 0.89; 95% Cl = 0.49-1.63, and the RR for case patient families with at least two nonprobands with prostate cancer was RR = 1.37; 95% Cl =■ 0.34-5.55. The three corresponding RRs for endometrial cancer were RR = 0.68 (95% Cl -0.39-1.18), RR = 1.11 (95% Cl = 0.43-2.85), and RR = 1.94 (95% Cl = 0.26-14.20), respec tively. The data were too sparse to do similar comparisons for ovarian cancer.
Risks for cancer of the breast and ovary were hardly modified by the age at diagnosis of the proband (Table 3 ). The RR of breast cancer for first-degree relatives of prostate cancer case patients diagnosed at 56 years of age or older was RR = 1.03; 95% Cl = 0.76-1.38. For the relatives of prostate cancer case patients diagnosed younger than 56 years of age, the RR appeared to be even lower: RR = 0.95; 95% Cl = 0.60-1.48. For ovarian cancer, these RRs were RR = 0.81; 95% Cl = 0.26-2.55 and RR = 1.00; 95% Cl = 0.21-4.82, respectively. The risk of endometrial cancer for relatives of young prostate cancer pro bands appeared to be somewhat higher (RR = 1.34; 95% Cl = Journal of the National Cancer Institute, Vol. 87, No. 13, July 5,1995 ARTICLES In the second part of the analysis, the 690 families were grouped according to the family history of prostate cancer: sporadic, familial, and hereditary. The 31 hereditary families were combined with an additional 75 multiplex families for a total of 106 in this last group. The 75 multiplex families had 237 first-degree relatives (offspring excluded) with cancer other than prostate cancer. Twenty-two of them had. an unknown age of diagnosis and were therefore excluded from the analysis. The remaining 215 relatives (77 males and 138 females) had a mean age of 65.3 years (±SD =16.1 years). Forty-two primary cancers were diagnosed among these relatives. The most prevalent sites were the breast (n = 9), lung (n = 9), and colorectum (n = 8).
There was no clear increasing trend in statistically significant higher risks for cancer at other major tumor sites, such as breast» ovary, or endometrium (Table 4) . Most RRs fluctuate around the null value. However, a statistically significant higher risk was found for tumors of the central nervous system in hereditary cancer families (RR = 3.02; 95% Cl = 1.08-8.41) and for other sites in the familial (RR = 2.35; 95% Cl = 1.08-5.14) and hereditary groups (RR = 3.00; 95% Cl = 1.18-7.63).
Discussion
This study presents an exploratory analysis of the risk of other malignancies among relatives of prostate cancer probands and tests for possible modifying effects of such malignancies on *RRs are adjusted for the effects of sex and age (>65 years versus <65 years). t Defined as simplex (single-case) families (n = 511). tDefined as families that had a positive family history of prostate cancer but did not meet one of the three criteria of the hereditary group (n = 148). §Defined as families that met one of the following criteria: 1) had a cluster of three or more relatives affected with prostate cancer within any nuclear family» such as a father and two sons affected or a group of three brothers affected; 2) prostate cancer occurred in each of three successive generations in either the probands' paternal lineage or maternal lineage; or 3) had a cluster of two relatives, both affected with prostate cancer at 65 years of age or younger. These three criteria were based on the resulLs of a test of various models to explain familial clustering (n = 106 [includes 31 hereditary families identified in the current study plus 75 referred multiplex families]).
the risk of prostate cancer among male relatives. We found that the risk for prostate cancer is 76% higher among first-degree relatives of prostate cancer case patients compared with first-de gree relatives of control subjects. This higher risk does not seem to be modified by the presence of an additional breast cancer case in the nuclear family, but our study's power to detect statis tically significant differences in risk was fairly small. Further more, the risks for other tumor sites are not increased among relatives of prostate cancer patients. The absence of an increased risk for breast cancer, ovarian cancer, and endometrial cancer in so-called hereditary cancer families is especially worth noting. In fact, of the 690 prostate cancer families, only five had two breast cancer cases and one had three breast cancer cases in the nuclear family. There was only one family with two endometrial cancer cases in the nuclear family. Of these seven prostate can cer families, six were classified as sporadic, one as familial, and none as hereditary for prostate cancer. Although previous casecontrol studies demonstrated an association between breast can cer and prostate cancer using breast cancer probands, our study shows differing results using prostate cancer probands,
We did see, however, an increased risk for tumors of the central nervous system and other sites among the hereditary families (the group of other tumors mainly consists of illdefined tumors of the musculoskeletal system, such as cancer of the hip and cancer of the back). This finding may reflect reality, but it may also be a chance finding due to small numbers. Another possible explanation is misclassification of tumor site. The interviewees may have remembered the site of distant metastases (brain or bone) in their relatives with cancer instead of the primary tumor site. In that case, the RRs for some of the primary sites listed in Table 4 will have been slightly underes timated.
All the analyses in this study were adjusted for age and sex. Data on other etiologic factors in relatives were not available for our study. To minimize the number of strata in the analysis, age of relatives was dichotomized into two strata, younger than 65 years of age and 65 years of age and older. Because age repre sents a very strong risk factor for all cancers, we checked for the existence of residual confounding by performing a reanalysis in which age was categorized into more strata. Results of this analysis were essentially unchanged.
By using Poisson regression analyses, we did not adjust for the inherent dependency of the data within each pedigree. Al though the estimated RRs should not be biased because of this dependency, their variances might have been slightly underes timated (i.e., the CIs may be too narrow). We have checked the degree of bias in the variances by reanalyzing familial clustering of prostate cancer and familial clustering of prostate cancer with breast cancer, using the computer program MULCOX2 (16). In this program, marginal distributions of multivariate failure times are formulated with Cox's proportional hazards modeling (17) while leaving the nature of dependence among related failure time completely unspecified. The results of these analyses were identical to those we obtained with Poisson regression (both the point estimates and the CIs). Because in these Cox analyses age (of relatives) is used as the time scale, we obtained additional evidence of the absence of confounding by age.
To increase the power to detect differences in the risks of can cer among relatives of sporadic, familial, and hereditary prostate cancer case patients, we enriched the hereditary families with 75 additional multiplex families. These multiplex families com prised a highly select group, and the data on cancer occurrence in these families were collected outside the context of the casecontrol study. Therefore, we performed an additional analysis on these multiplex families only to check the validity of our results. We compared the observed number of selected tumor sites with the expected numbers on the basis of general popula tion incidence data and person-years at risk. For the population incidence data, we extracted the age-specific, sex-specific, and calendar-year-specific incidence rates from the United States Data Registry program, version 58a (75). These data represent the incidence rates from the Connecticut Cancer Registry from 1925 to 1975. We updated the rates to 1987, using volume 5 and volume 6 of Cancer Incidence in Five Continents (19, 20) . CIs of the observed/expected ratios were calculated using Byar's ap proximation of the exact Poisson test (21).
In total, 48 cancers were observed among the first-degree relatives (offspring included) of the 75 probands, where 49.5 were expected (RR = 0.97; 95% Cl = 0.71-1.29). The ob served/expected ratios for specific sites were as follows: colorectal cancer-RR = 1,06; 95% Cl = 0.48-2.01, respiratory tract cancer-RR = 1.61; 95% Cl = 0.73-3.05, breast cancer-RR = 0.96; 95% Cl = 0.44-1.82, endometrial cancer-RR = 0.45; 95% Cl = 0.01-2.53, and ovarian cancer-RR = 1.25; 95% Cl = 0.14-4.51.
Thus, even among families that were highly selected because of the presence of prostate cancer, the risks for cancer at other sites appeared not to be increased. This finding means that hereditary prostate cancer appears to be relatively site-specific and that it does not seem to be part of another hereditary cancer syndrome. Identification of a gene or genes through ongoing and future linkage analyses should provide a better under standing of the more common hereditary cancers such as pros tate cancer.
